Professor Chris Lord is Team Leader of the CRUK Gene Function Laboratory and Reader in Cancer Genomics and Therapeutics in the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research, London. Much of the focus of his work is in exploiting genetic concepts such as synthetic lethality and functional genomics approaches to understand the behaviour of tumour cells. The ultimate aim of this work is to use this information to design novel ways to treat the disease.
In recent years Professor Lord’s team have used these approaches to understand how PARP inhibitors might be used to treat cancer and to develop novel drugs such as Tankyrase inhibitors. In addition, the laboratory has focussed on identifying and validating novel targets for use in breast cancer as well as dissecting the genetic control of drug sensitivity and drug resistance in this disease.
Professor Lord studied Biochemistry at the University of Surrey and completed his DPhil in 1997, working on complex disease genetics at the Wellcome Trust Centre for Human Genetics, University of Oxford. After a post-doctoral position at the Cambridge Institute of Medical Research, University of Cambridge, he joined the ICR in 2000, becoming a Staff Scientist in 2005, Senior Staff Scientist in 2008 and a Reader in 2014.
Disclosure information: Professor Lord is an inventor on patents describing the use of PARP inhibitors and stands to gain from their development as part of the ICR’s “Rewards to Inventors” scheme. He has received honoraria, consultancy or advisory board payments from the following: Sun Pharma, Vertex Ltd., 3rd Rock, Horizon Discovery, Gerson Lehrman Group, Astra Zeneca, Merck KGaA and LEK.
Professor Lord serves as a member of the Athena SWAN steering group.